<DOC>
	<DOCNO>NCT01236391</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy ibrutinib participant relapse refractory MCL . The secondary objective evaluate safety fix daily dose regimen ( 560 mg daily ) PCI-32765 population .</brief_summary>
	<brief_title>Safety Efficacy PCI-32765 Participants With Relapsed/Refractory Mantle Cell Lymphoma ( MCL )</brief_title>
	<detailed_description>This Phase 2 , open-label , nonrandomized , multicenter , monotherapy study subject histologically document MCL relapse ≥ 1 ( &gt; 5 ) prior treatment regimen . All subject meet eligibility criterion receive PCI-32765 capsule dosage 560 mg/day daily 28-day cycle disease progression , unacceptable toxicity , enrollment long-term extension study , whichever occur early .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Men woman ≥ 18 year age ECOG performance status ≤ 2 Pathologically confirm MCL , documentation either overexpression cyclin D1 ( 11 ; 14 ) , measurable disease cross sectional imaging ≥ 2 cm long diameter measurable 2 perpendicular dimension Documented failure achieve least partial response ( PR ) , document disease progression disease , recent treatment regimen At least 1 , 5 , prior treatment regimen MCL ( Note : Subjects receive ≥2 cycle prior treatment bortezomib , either single agent part combination therapy regimen , consider bortezomibexposed . ) Willing able participate require evaluation procedure study protocol include swallow capsule without difficulty Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) Major exclusion criterion : Prior chemotherapy within 3 week , nitrosoureas within 6 week , therapeutic anticancer antibody within 4 week , radio toxinimmunoconjugates within 10 week , radiation therapy within 3 week , major surgery within 2 week first dose study drug Any lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism PCI32765 capsule , put study outcome undue risk Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction Any follow laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 750 cells/mm3 ( 0.75 x 109/L ) unless document bone marrow involvement 2 . Platelet count &lt; 50,000 cells/mm3 ( 50 x 109/L ) independent transfusion support unless document bone marrow involvement 3 . Serum aspartate transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) ≥ 3.0 x upper limit normal ( ULN ) 4 . Creatinine &gt; 2.0 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Pharmacyclics</keyword>
	<keyword>Mantle</keyword>
	<keyword>Mantle Cell</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkins</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>Naive</keyword>
	<keyword>PCYC</keyword>
</DOC>